Charles River Labs Announces Interim CFO Appointment Following CFO Resignation

Details

announced on September 12, 2025, that Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer (CFO), has resigned effective September 29, 2025. Michael G. Knell, Corporate Senior Vice President and Chief Accounting Officer, has been appointed as the interim CFO. The company has begun a search for a permanent successor. The resignation is not due to any disagreements with the company, and the company has reaffirmed its 2025 financial guidance. On September 16, 2025, the company issued a press release announcing these changes.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.